EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression

Jean-Christophe Corvol iD, Mickael Alexandre Obadia, Caroline Moreau, Louise-Laure Mariani, Jean-Philippe Brandel, David Devos, Sara Sambin, Nicolas Carrière, Günter Höglinger iD, Marie Lebouteux, Graziella Mangone, Noelle Callizot und 6 weitere

Movement Disorders · 2025-12 · 40 (12) · 2700-2709

DOI: 10.1002/mds.70049 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 27.09.2025. Verfasst von Jean-Christophe Corvol und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Assistance Publique Hôpitaux de Paris, Paris Brain Institute, ICM, Inserm, CNRS, Department of Neurology, CIC Neurosciences, Hôp…. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim was to evaluate the safety, tolerability, pharmacokinetics, and potential clinical efficacy of AZP2006, an oral pleiotropic drug modulating progranulin levels, in patients with progressive supranuclear palsy (PSP), a rare tauopathy.

Methods

A randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted at three sites in France. Eligible participants (age 40–80 years, diagnosed with probable or possible PSP) were randomized to receive AZP2006 (60 mg once per day [QD] or 80/50 mg QD [80 mg for 10 days followed by 50 mg]) or placebo for 12 weeks. Assessments included safety, pharmacokinetics (plasma and whole blood), pharmacodynamics (cerebrospinal fluid and plasma biomarkers), and exploratory clinical efficacy (PSP rating scale, clinical global impression, and activities of daily living). Approximately 2 years post‐trial, an open‐label extension (OLE) enrolled 15 patients who received active treatment (AZP2006) for 6 months.

Results

Forty‐one patients were screened, 36 randomized, and 34 completed the study. AZP2006 demonstrated acceptable tolerability and safety with no treatment‐related serious adverse events. Pharmacokinetic analysis confirmed rapid absorption, a long half‐life (60 mg: 764.3 hours; 80/50 mg: 684.7 hours), and steady‐state by day 45 (60 mg) and day 28 (80/50 mg). Biomarker analyses indicated blood–brain barrier crossing, target engagement, and stabilized progranulin levels. Trends in efficacy favored slower disease progression in AZP2006 groups. The OLE demonstrated a slowed progression of the disease and revealed no notable safety concerns.

Conclusions

AZP2006 was well‐tolerated and demonstrated favorable trends in biomarker and clinical outcomes. These preliminary signals support further investigation to determine whether a meaningful clinical benefit can be achieved in PSP with AZP2006. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Supranuclear Palsy, ProgressiveHumansAgedMaleFemaleMiddle AgedDouble-Blind MethodDisease ProgressionAged, 80 and overBiomarkersAdultProgranulinsTreatment Outcome

Stichwörter der Autor:innen

lysosomeprogranulinprogressive supranuclear palsytauopathy

Substanzen

BiomarkersProgranulins

Autor:innen und Institutionen

  • Sorbonne Université, Assistance Publique Hôpitaux de Paris, Paris Brain Institute, ICM, Inserm, CNRS, Department of Neurology, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
  • Hospital Foundation Adolphe de Rothschild, Neurology Federation, Parkinson Unit, Paris, France.
  • Lille University. Inserm 1172, Department of Neurology, CHU Lille, Lille, France.
  • Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU), German Center for Neurodegenerative Diseases (DZNE), Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Alzprotect, Loos, France.

ORCID-Profile: Jean-Christophe Corvol, Günter Höglinger, Philippe Verwaerde

Zitieren

APA

Corvol, J. C., Obadia, M. A., Moreau, C., Mariani, L. L., Brandel, J. P., Devos, D., Sambin, S., Carrière, N., Höglinger, G., Lebouteux, M., Mangone, G., Callizot, N., Blondel, A., Defert, O., Estrella, C., Karapet, A., Verwaerde, P., & Defebvre, L. (2025). AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression. Movement Disorders, 40(12), 2700-2709. https://doi.org/10.1002/mds.70049

Vancouver

Corvol JC, Obadia MA, Moreau C, Mariani LL, Brandel JP, Devos D, et al. AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression. Movement Disorders. 2025;40(12):2700-2709. doi:10.1002/mds.70049

BibTeX
@article{Corvol2025,
  author = {Corvol, Jean-Christophe and Obadia, Mickael Alexandre and Moreau, Caroline and Mariani, Louise-Laure and Brandel, Jean-Philippe and Devos, David and Sambin, Sara and Carrière, Nicolas and Höglinger, Günter and Lebouteux, Marie and Mangone, Graziella and Callizot, Noelle and Blondel, Aurélien and Defert, Olivier and Estrella, Cecilia and Karapet, Artin and Verwaerde, Philippe and Defebvre, Luc},
  title = {AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression},
  journal = {Movement Disorders},
  year = {2025},
  volume = {40},
  number = {12},
  pages = {2700--2709},
  doi = {10.1002/mds.70049}
}
Kostenlos starten →